Comparative Pharmacology
Head-to-head clinical analysis: XYZAL versus ZYRTEC ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: XYZAL versus ZYRTEC ALLERGY.
XYZAL vs ZYRTEC ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocetirizine is a selective histamine H1-receptor antagonist; it inhibits the histamine-mediated responses in allergic conditions.
Selective peripheral histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils.
5 mg orally once daily in the evening.
5–10 mg orally once daily; maximum dose 10 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours in healthy adults; prolonged to 8–11 hours in elderly and in renal impairment.
Terminal elimination half-life is approximately 8.3 hours (range 6–10 hours) in healthy adults, prolonged to 20–25 hours in patients with renal impairment (CrCl < 40 mL/min). No significant difference in elderly vs. young adults with normal renal function.
Approximately 84% of a dose is excreted renally as unchanged drug; 12% in feces via biliary elimination.
Renal excretion of unchanged drug accounts for approximately 70% of elimination; approximately 10% is excreted in feces via biliary route. Total renal excretion includes both parent drug and metabolites, with cetirizine largely unchanged.
Category C
Category C
Antihistamine
Antihistamine